Candel Therapeutics
Candel Therapeutics is a biotechnology company focused on developing viral immunotherapies for cancer, utilizing platforms like CAN-2409 and CAN-3110 to induce individualized immune responses against tumors.
Company Overview
Candel Therapeutics is focused on developing viral immunotherapies that empower the immune system to combat cancer. These investigational therapies provide individualized responses tailored to each patient and their specific type of cancer, aiming for long-lasting protection. The company is headquartered at 117 Kendrick St, Suite 450, Needham, MA 02494.
Clinical Trials
Candel Therapeutics is conducting a randomized controlled phase 3 clinical trial involving CAN-2409, an adenovirus platform therapy. This trial pairs CAN-2409 with valacyclovir and standard radiation therapy, targeting patients with localized intermediate or high-risk prostate cancer. The company's clinical trials also address diseases such as prostate cancer, brain cancer, pancreatic cancer, and lung cancer.
Innovative Therapies
Candel Therapeutics offers groundbreaking therapies, including CAN-2409 and CAN-3110. CAN-2409 is an adenovirus platform-based off-the-shelf therapy that provides an individualized cancer response. CAN-3110 is an oncolytic virus therapy derived from the herpes simplex virus platform, characterized by tumor-specificity. These therapies are designed for a favorable benefit-to-risk profile.
EnLIGHTEN™ Discovery Platform
The EnLIGHTEN™ Discovery Platform is a key technology used by Candel Therapeutics to develop new viral immunotherapies for solid tumors. This platform is instrumental in creating therapies that aim to produce a completely individualized response for each patient, optimizing cancer treatment strategies.